Iparomlimab
Gastric Cancer (GC)
Qilu Pharmaceutical Co., Ltd.Phase 1/2Active
CC
45/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 81/ 100
Competitive context
16 Active assets in the Gastric Cancer (GC) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
qls5132 Qilu Pharmaceutical Co., Ltd. | Phase 1/2 | CC |
Olaparib Qilu Pharmaceutical Co., Ltd. | Phase 1/2 | CC |
ql2107 Qilu Pharmaceutical Co., Ltd. | Phase 1/2 | CC |
xh001 Shenzhen Xinhe Biomedical | Phase 1 | CC |
okn4395 Epkin | Phase 1 | CC |
View all 16 →
Same molecule, other indications
Iparomlimab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →